Severe hypoglycaemia in type 1 diabetes mellitus: Underlying drivers and potential strategies for successful prevention

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 3, 2014, Pages 175-190

  Little, S A ^a   Leelarathna, L ^b   Barendse, S M ^c   Walkinshaw, E ^d   Tan, H K ^e   Lubina Solomon, A ^d   de Zoysa, N ^f   Rogers, H ^f   Choudhary, P ^f   Amiel, S A ^f   Heller, S R ^d   Evans, M ^b   Flanagan, D ^e   Speight, J ^c,g,h   Shaw, J A M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c AHP Research   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e PENINSULA MEDICAL SCHOOL   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g THE AUSTRALIAN CENTRE FOR BEHAVIOURAL RESEARCH IN DIABETES   (Australia)

^h DEAKIN UNIVERSITY   (Australia)

Author keywords

Hypoglycaemia; Impaired awareness of hypoglycaemia; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

AUTONOMIC DYSFUNCTION; AWARENESS; BEHAVIOR THERAPY; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DISEASE SEVERITY; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MEDICAL EDUCATION; NEUROIMAGING; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY;

HYPOGLYCAEMIA; IMPAIRED AWARENESS OF HYPOGLYCAEMIA; TYPE 1 DIABETES;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84894232227     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2492     Document Type: Review

References (140)

1. Banting F, Best C, Collip J, Campbell W, Fletcher A. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922; 12: 141-146.
2. Fletcher A, Campbell W. The blood sugar following insulin administration and the symptom complex: hypoglycaemia. J Metab Res 1922; 2: 637-649.
3. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-986.
4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342(6): 381-389.
5. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45(7): 937-948.
6. ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28(5): 1245-1249.
7. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005; 54(12): 3592-3601.
8. DCCT. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991; 90(4): 450-459.
9. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991; 8(3): 217-222.
10. Gonder-Frederick LA, Schmidt KM, Vajda KA, et al. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care 2011; 34(4): 801-806.
11. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26(6): 1902-1912.
12. Tattersall RB, Gill GV. Unexplained deaths of type-1 diabetic-patients. Diabetic Med 1991; 8(1): 49-58.
13. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Characterizing sudden death and dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 diabetes registries. Diabet Med 2011; 28(3): 293-300.
14. Gonder-Frederick LA, Cox DJ, Bobbitt SA, Pennebaker JW. Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Health Psychol 1989; 8(1): 45-59.
15. Ritholz MD, Jacobson AM. Living with hypoglycemia. J Gen Intern Med 1998; 13(12): 799-804.
16. Speight J, Woodcock AJ, Reaney MD, et al. 'The QoL-Q Diabetes' - a novel instrument to assess quality of life for adults with type 1 diabetes undergoing complex interventions including transplantation. Diabet Med 2010; 27(Suppl. 1): 3-4.
17. Swinnen SG, Mullins P, Miller M, Hoekstra JB, Holleman F. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 2009; 52(1): 38-41.
18. Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia 2009; 52(1): 31-34.
19. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20(6): 479-486.
20. ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000; 23(10): 1467-1471.
21. UK-hypoglycaemia-studygroup. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50(6): 1140-1147.
22. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011; 13(Suppl 1): S53-S64.
23. Fanelli C, Pampanelli S, Epifano L, et al. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia 1994; 37(8): 797-807.
24. Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260(1 Pt 1): E67-E74.
25. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79(3): 777-781.
26. Amiel SA, Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans. Diabetes 1987; 36(4): 518-522.
27. Bolli G, de Feo P, Compagnucci P, et al. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 1983; 32(2): 134-141.
28. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 2002; 51(4): 958-965.
29. Paranjape SA, Chan O, Zhu W, et al. Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 2010; 59(6): 1521-1527.
30. Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 1979; 64(1): 62-71.
31. Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37(12): 1265-1276.
32. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988; 37(7): 901-907.
33. Davis MR, Shamoon H. Counterregulatory adaptation to recurrent hypoglycemia in normal humans. J Clin Endocrinol Metab 1991; 73(5): 995-1001.
34. Widom B, Simonson DC. Intermittent hypoglycemia impairs glucose counterregulation. Diabetes 1992; 41(12): 1597-1602.
35. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991; 40(2): 223-226.
36. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91(3): 819-828.
37. Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes 1992; 41(3): 255-260.
38. Sussman KE, Crout JR, Marble A. Failure of warning in insulin-induced hypoglycemic reactions. Diabetes 1963; 12: 38-45.
39. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008; 25(4): 501-504.
40. Cryer PE. Hypoglycemia begets hypoglycemia in IDDM. Diabetes 1993; 42(12): 1691-1693.
41. DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004; 287(1): E32-E41.
42. DCCT. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46(2): 271-286.
43. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46(2): 271-286.
44. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17(7): 697-703.
45. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995; 18(4): 517-522.
46. Gonder-Frederick L, Cox D, Kovatchev B, Schlundt D, Clarke W. A biopsychobehavioral model of risk of severe hypoglycemia. Diabetes Care 1997; 20(4): 661-669.
47. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010; 33(3): e36.
48. Cox DJ, Gonder-Frederick L, Polonsky W, Schlundt D, Kovatchev B, Clarke W. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24(4): 637-642.
49. Anderbro T, Amsberg S, Adamson U, et al. Fear of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2010; 27(10): 1151-1158.
50. Barendse S, Singh H, Little S, et al. Drivers of recurrent severe hypoglycaemia and implications for its prevention: a qualitative study of adults with type 1 diabetes. Diabetic Med 2012; 29(Suppl. 1): 131.
51. Singh H, Gonder-Frederick LA, Schmidt KM, Ford D, Hawley JS, Cox DJ. Fear of hyperglycaemia in people with type 1 diabetes. Diabetes 2010; 59(1): A-522, Abstract 1992-P.
52. Barendse SM, Singh H, Cox D, et al. Cultural adaption of the Hyperglycaemia Avoidance Scale (HAS) for use in the UK and modifications to improve suitability for insulin pump and continuous glucose monitoring users. Diabetic Med 2011; 28(suppl. 1): 181 (abstract).
53. Rogers HA, de Zoysa N, Amiel SA. Patient experience of hypoglycaemia unawareness in type 1 diabetes: are patients appropriately concerned? Diabet Med 2012; 29(3): 321-327.
54. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008; 57(2): 470-475.
55. Teh MM, Dunn JT, Choudhary P, et al. Evolution and resolution of human brain perfusion responses to the stress of induced hypoglycemia. Neuroimage 2010; 53(2): 584-592.
56. Bingham EM, Dunn JT, Smith D, et al. Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-D-glucose PET study. Diabetologia 2005; 48(10): 2080-2089.
57. Dunn JT, Cranston I, Marsden PK, Amiel SA, Reed LJ. Attenuation of amydgala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 2007; 56(11): 2766-2773.
58. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5): 1553-1579.
59. Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes-mellitus. Serono Sym 1992; 89: 353-898.
60. Ryder RE, Owens DR, Hayes TM, Ghatei MA, Bloom SR. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. BMJ 1990; 301(6755): 783-787.
61. Stephenson JM, Kempler P, Perin PC, Fuller JH. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996; 39(11): 1372-1376.
62. Horie H, Hanafusa T, Matsuyama T, et al. Decreased response of epinephrine and norepinephrine to insulin-induced hypoglycemia in diabetic autonomic neuropathy. Horm Metab Res 1984; 16(8): 398-401.
63. Hilsted J, Madsbad S, Krarup T, et al. Hormonal, metabolic, and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes 1981; 30(8): 626-633.
64. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. The adrenal medullary response to hypoglycemia in patients with orthostatic hypotension. J Clin Endocrinol Metab 1980; 51(6): 1401-1406.
65. Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21(11): 1960-1966.
66. Hepburn DA, Patrick AW, Eadington DW, Ewing DJ, Frier BM. Unawareness of hypoglycaemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 1990; 7(8): 711-717.
67. Mitrakou A, Fanelli C, Veneman T, et al. Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 1993; 329(12): 834-839.
68. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42(11): 1683-1689.
69. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344(8918): 283-287.
70. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43(12): 1426-1434.
71. Dagogo-Jack S, Fanelli CG, Cryer PE. Durable reversal of hypoglycemia unawareness in type 1 diabetes. Diabetes Care 1999; 22(5): 866-867.
72. Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care 1995; 18(4): 523-528.
73. Schachinger H, Hegar K, Hermanns N, et al. Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany. J Behav Med 2005; 28(6): 587-594.
74. Kinsley BT, Weinger K, Bajaj M, et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999; 22(7): 1022-1028.
75. Cox D, Ritterband L, Magee J, Clarke W, Gonder-Frederick L. Blood glucose awareness training delivered over the internet. Diabetes Care 2008; 31(8): 1527-1528.
76. Hermanns N, Kulzer B, Kubiak T, Krichbaum M, Haak T. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metab Res Rev 2007; 23(7): 528-538.
77. Muhlhauser I, Jorgens V, Berger M, et al. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22months. Diabetologia 1983; 25(6): 470-476.
78. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care 2012; 35(8): 1638-1642.
79. McIntyre HD, Knight BA, Harvey DM, Noud MN, Hagger VL, Gilshenan KS. Dose adjustment for normal eating (DAFNE) - an audit of outcomes in Australia. Med J Australia 2010; 192(11): 637-640.
80. Rogers H, Turner E, Thompson G, Hopkins D, Amiel SA. Hub-and-spoke model for a 5-day structured patient education programme for people with Type 1 diabetes. Diabet Med 2009; 26(9): 915-920.
81. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23(2): 157-162.
82. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23(5): 639-643.
83. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005; 35(9): 536-542.
84. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21(11): 1213-1220.
85. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26(5): 1490-1496.
86. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006; 23(3): 285-292.
87. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996; 85(3): 304-308.
88. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1): 73-82.
89. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25(4): 442-449.
90. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006; 23(7): 729-735.
91. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26(3): 590-596.
92. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24(6): 635-642.
93. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009; 31(10): 2086-2097.
94. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379(9825): 1489-1497.
95. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98(3): 1154-1162.
96. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37(7): 713-720.
97. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999; 22(10): 1607-1611.
98. Ahmed AB, Home PD. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care 1998; 21(1): 32-37.
99. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000; 17(3): 209-214.
100. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20(12): 1827-1832.
101. Heller SR, Amiel SA, Evans ML, Kong MF, Macdonald IA, Peacey SR. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen? Diabetes Obes Metab 2002; 4(2): 106-112.
102. Heinemann L, Kapitza C, Starke AA, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet Med 1996; 13(7): 683-684.
103. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21(11): 1904-1909.
104. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract 2001; 54(2): 105-114.
105. Continuous subcutaneous insulin infusion. Diabetes Care 2004; 27(Suppl 1): S110.
106. NICE. 2008. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus, www.guidance.nice.org.uk/TA151.
107. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324(7339): 705.
108. Jacobsen IB, Henriksen JE, Hother-Nielsen O, Vach W, Beck-Nielsen H. Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Res Clin Pract 2009; 86(1): 1-10.
109. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51(6): 941-951.
110. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26(4): 1079-1087.
111. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; (1): CD005103.
112. Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabet Med 2007; 24(7): 778-783.
113. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32(7): 1170-1176.
114. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28(3): 533-538.
115. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25(7): 765-774.
116. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol Ther 2000; 2(3): 461-472.
117. Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Reproducibility and reliability of hypoglycaemic episodes recorded with Continuous Glucose Monitoring System (CGMS) in daily life. Diabet Med 2005; 22(7): 858-862.
118. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359(14): 1464-1476.
119. JDRF-CGM-study-group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32(8): 1378-1383.
120. Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32(11): 1947-1953.
121. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363(4): 311-320.
122. Hermanides J, Nørgaard K, Bruttomesso D, et al. Sensor augmented pump therapy substantially lowers HbA1c; a randomized controlled trial. Diabetologia 2009; 52(Suppl 1): S43. abstract.
123. Raccah D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009; 32(12): 2245-2250.
124. Garg SK, Voelmle MK, Beatson CR, et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care 2011; 34(3): 574-579.
125. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011; 34(4): 795-800.
126. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008; 10(5): 377-383.
127. Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005; 7(3): 440-447.
128. Ly TT, Hewitt J, Davey RJ, Lim EM, Davis EA, Jones TW. Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucose monitoring in adolescents with type 1 diabetes. Diabetes Care 2011; 34(1): 50-52.
129. Cemeroglu AP, Stone R, Kleis L, Racine MS, Postellon DC, Wood MA. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. Pediatr Diabetes 2010; 11(3): 182-187.
130. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34(9): 2023-2025.
131. Danne T, Kordonouri O, Holder M, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13(11): 1129-1134.
132. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342: d1855.
133. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33(6): 1282-1287.
134. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009; 373(9677): 1808-1817.
135. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25, 000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011; 8(1): 6-16.
136. NICE. 2008. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus, Interventional Procedure Guidance 257 http://www.nice.org.uk/ipg257.
137. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4): 230-238.
138. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355(13): 1318-1330.
139. Cure P, Pileggi A, Froud T, et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation 2008; 85(6): 801-812.
140. Leitao CB, Tharavanij T, Cure P, et al. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care 2008; 31(11): 2113-2115.